United States of America based
Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.
TechnologiesAI Companies (Drug Discovery) Pharmaceutical and Drug Discovery
Posts Mentioning This Company
Conduct experimental biology at scale by testing thousands of compounds on hundreds of cellular disease models in parallel. Allows researchers to: Rapidly identify new indications for many known drugs and shelved assets.
Rec-994 for Cerebral Cavernous Malformation
Cerebral cavernous malformation (CCM) is a rare, genetic disease that affects up to 1.5 million people in the U.S. CCM is defined as a collection of small blood vessels in the brain — malformations — that are enlarged and irregular and can lead to altered blood flow.
REC-994 is Recursion’s first clinical program, discovered using a basic machine learning system that was the seed for Recursion’s drug discovery platform. REC-994 is a well-characterized, small molecule that has been granted Orphan Drug Designation by the U.S. FDA for the potential treatment of symptomatic CCM and by the European Medicines Agency for the potential treatment of familial CCM.
Recursion has successfully completed Phase 1 studies, and the team is currently preparing REC-994 for Phase 2 clinical trials.
Rec-2282 for Neurofibromatosis
type 2 (NF2)
Neurofibromatosis type 2 (NF2) is a rare, genetic disease most commonly associated with benign, non-cancerous tumours that occur on the nerves responsible for balance and hearing in the inner ear (known as acoustic neuromas). It’s estimated that 1 in 33,000 people worldwide are affected by NF2. Mutations in the NF2 gene also drive other oncology conditions.
REC-2282 was discovered on Recursion’s platform after a search for potential therapies for NF2 revealed the clinical candidate among shelved compounds with the promise for accelerated development. Recursion in-licensed the compound from Ohio State University to be developed for NF2.
Our first wholly owned subsidiary company, CereXis, Inc., is currently preparing REC-2282 for Phase 2 clinical trials. For more information, please visit their website.
No services posted yet